WO2016159897A1 - Potassium citrate suspension - Google Patents
Potassium citrate suspension Download PDFInfo
- Publication number
- WO2016159897A1 WO2016159897A1 PCT/TR2015/000136 TR2015000136W WO2016159897A1 WO 2016159897 A1 WO2016159897 A1 WO 2016159897A1 TR 2015000136 W TR2015000136 W TR 2015000136W WO 2016159897 A1 WO2016159897 A1 WO 2016159897A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- suspension according
- potassium citrate
- pharmaceutical
- pharmaceutical suspension
- sodium
- Prior art date
Links
- QEEAPRPFLLJWCF-UHFFFAOYSA-K Potassium citrate Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 title claims description 23
- 239000001508 potassium citrate Substances 0.000 title claims description 23
- 229960002635 potassium citrate Drugs 0.000 title claims description 23
- 235000015870 tripotassium citrate Nutrition 0.000 title claims description 23
- 239000011791 tripotassium citrate Substances 0.000 title claims description 23
- 239000000725 suspension Substances 0.000 title claims description 8
- PJAHUDTUZRZBKM-UHFFFAOYSA-K potassium citrate monohydrate Chemical compound O.[K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PJAHUDTUZRZBKM-UHFFFAOYSA-K 0.000 claims abstract description 12
- 229940050931 potassium citrate monohydrate Drugs 0.000 claims abstract description 9
- 229940100692 Oral Suspension Drugs 0.000 claims abstract description 7
- 206010029148 Nephrolithiasis Diseases 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 235000003599 food sweetener Nutrition 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 239000006184 cosolvent Substances 0.000 claims description 4
- 238000005755 formation reaction Methods 0.000 claims description 4
- 239000000375 suspending agent Substances 0.000 claims description 4
- 229960005359 PROPYLPARABEN SODIUM Drugs 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229960003476 methylparaben sodium Drugs 0.000 claims description 3
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 claims description 3
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 claims description 3
- BAQAVOSOZGMPRM-JVFSCRHWSA-N (2R,3R,4R,5R,6R)-2-[(2S,3R,4R,5R)-2,5-bis(chloromethyl)-3,4-dihydroxyoxolan-2-yl]oxy-5-chloro-6-(hydroxymethyl)oxane-3,4-diol Chemical group O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@]1(CCl)[C@H](O)[C@@H](O)[C@H](CCl)O1 BAQAVOSOZGMPRM-JVFSCRHWSA-N 0.000 claims description 2
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 208000000913 Kidney Calculi Diseases 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- 229940116362 Tragacanth Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- 235000010487 tragacanth Nutrition 0.000 claims description 2
- 239000000196 tragacanth Substances 0.000 claims description 2
- 239000007971 pharmaceutical suspension Substances 0.000 claims 10
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 241000220479 Acacia Species 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 230000000069 prophylaxis Effects 0.000 abstract description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 239000004203 carnauba wax Substances 0.000 description 6
- 235000013869 carnauba wax Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000004575 stone Substances 0.000 description 6
- 229940079593 drugs Drugs 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000002485 urinary Effects 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- QXDMQSPYEZFLGF-UHFFFAOYSA-L Calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- 229940116269 Uric Acid Drugs 0.000 description 3
- 210000002700 Urine Anatomy 0.000 description 3
- 229940054512 Urocit-K Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 239000007968 orange flavor Substances 0.000 description 3
- 239000008371 vanilla flavor Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000011778 trisodium citrate Substances 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-N Acesulfame potassium Chemical compound [K+].CC1=CC(=O)NS(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 Aspartame Drugs 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000003980 Calcium Oxalate Nephrolithiasis Diseases 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 229940075232 Cytra-3 Drugs 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 240000005389 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229940010454 Licorice Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000016247 Mentha requienii Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229940100528 POLYOXYL 8 STEARATE Drugs 0.000 description 1
- 229960000502 Poloxamer Drugs 0.000 description 1
- 229940068918 Polyethylene Glycol 400 Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940068965 Polysorbates Drugs 0.000 description 1
- 229940037179 Potassium Ion Drugs 0.000 description 1
- 229940069338 Potassium Sorbate Drugs 0.000 description 1
- CHHHXKFHOYLYRE-STWYSWDKSA-M Potassium sorbate Chemical compound [K+].C\C=C\C=C\C([O-])=O CHHHXKFHOYLYRE-STWYSWDKSA-M 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 240000002799 Prunus avium Species 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229960003885 Sodium Benzoate Drugs 0.000 description 1
- 229960001462 Sodium Cyclamate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 206010046577 Urinary tract infection Diseases 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000006682 bigleaf mint Nutrition 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000014063 licorice root Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- -1 methylceilulose Polymers 0.000 description 1
- 235000006679 mint Nutrition 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940003452 potassium citrate 10 MEQ Drugs 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate dihydrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical class CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
Abstract
The present invention relates to the oral suspension comprising potassium citrate monohydrate between 540mg (5mEq) and 2160mg (20mEq) in 5ml for the treatment and prophylaxis of renal stones.
Description
POTASSIUM CITRATE SUSPENSION
DESCRIPTION
Potassium citrate alkalinizes the urine and reduces the formation of the two most common types of kidney stones: calcium oxalate and uric acid stones. The objective of treatment with Potassium Citrate is to restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6 or 7.
Also, potassium citrate helps relieve symptoms of cystitis and other mild urinary infections. It works by making urine less acidic and this helps relieve the discomfort caused by the infection.
The citrate moiety, which is largely oxidized, is absorbed while the K ion remains, leaving an alkali load. The alkali load increases urinary citrate and urinary pH. As a result, it decreases urinary saturation of calcium oxalate and inhibits both calcium oxalate and its crystallization.
Pharmaceuticals comprising potassium citrate is indicated for the management of renal tubuiar acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones.
Potassium citrate is a potassium salt of citric acid with the molecular formula C6H5K3O7. Molecular weight is 306,39 g/mol.
Potassium citrate monohydrate is white crystals, granules or powder. One gram dissolves in 0.65 ml water. The pH of aqueous solution is about 8.5.
5 mEq equals 540mg of potassium citrate monohydrate. Also potassium citrate 10 mEq equals 1080mg and 15mEq equals 1620mg of potassium citrate monohydrate.
US4888182 and US4966776 relate to methods and compositions for the treatment and prophylaxis of calcium renal stones by administering the patient a daily oral dosage of a composition consisting essentially of potassium citrate. The daily oral dosage of potassium citrate is between about 30 meq and about 120 meq.
A typical dosage scheme involves administering about 30 to 120 meq potassium citrate per day in divided doses. Such treatments are effective in dissolving existing calcium stones and preventing formation of new calcium stones. Moreover, the potassium citrate is superior to sodium citrate in the treatment of uric acid lithiasis. Potassium citrate therapy averts calcium renal stone formation, a complication which is often associated with sodium citrate or sodium bicarbonate alkalinization therapy.
CYTRA-3 Syrup contains Potassium Citrate Monohydrate 550 mg, Sodium Citrate Dihydrate 500 mg and Citric Acid Monohydrate 334 mg in each teaspoonful (5 ml_). Each 5 ml_ contains 1 mEq potassium ion and 1 mEq sodium ion and is equivalent to 2 mEq bicarbonate (HC03). This product alkalinizes the urine.
Mission Pharmacal (San Antonio, TX, USA) sells an extended-release potassium citrate tablet, Urocit-K, in three strengths: 5 -mEq, 10-meq, and 15- mEq tablets. The daily dose of Urocit-K is 30-60 mEq. Urocit-K is a wax matrix tablet containing potassium citrate, carnauba wax as extended-release agent, and magnesium stearate as lubricant.
US 4,904,478 teaches an extended-release wax matrix tablet of a highly water-soluble drug, sodium fluoride, wherein the carnauba wax, present at 35-70% w/w of the tablet weight, is dry mixed with the drug and other inactive ingredients prior to compression. In the case of potassium citrate, because the drug dosage is high, the inactive ingredients including the extended-release agent(s) must be kept below 25% w/w to keep the tablet size acceptable for swallowing. If carnauba wax is used at less than 25% w/w, Example 1 of US 2008/0131504 A! discloses that the drug and carnauba wax should be heated until the carnauba wax liquefies, to give an acceptable extended-release profile and abrasion.
WO 2014051443 relates to the extended-release potassium citrate tablets containing carnauba wax can be produced without melting the wax.
SUMMARY OF THE INVENTION
The present invention provides a pharmaceutical oral suspension composition comprising potassium citrate for the treatment and prophylaxis of calcium renal stones in persons susceptible to such stone formations. (The terms of potassium citrate and potassium citrate monohydrate describes same compound.)
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to manufacture a pharmaceutical oral suspension form of high dosage potassium citrate having improved physico-chemical properties so that their use by patients.
The pharmaceutical oral suspension comprises potassium citrate monohydrate between 540mg (5mEq) and 2160mg (20mEq) in 5ml, preferably 216Gmg (20mEq) in 5ml.
According to the present invention, a stable and easily pourable pharmaceutical composition prepares in the form of a suspension comprising potassium citrate.
The suspensions suitable for oral administration are aqueous-based. When an organic co- solvent is employed it is preferred that it is used in amounts of 0.5 to 10% (g/ml) of the total composition. Suitable solvents are those water-miscible solvents commonly used in the art, e. g., glycerol, propylene glycol (1 ,2-propane dio!), polyethylene glycol 300, polyethylene glycol 400 and ethanol. Preferably, glycerol is selected as co-solvent in the composition.
Oral suspensions according to the invention may contain other exctpients commonly employed in oral suspensions in order to provide the required stability and therapeutic efficacy.
Suspending agents can be any convenient agents known in the art for this purpose. The composition comprises at least one compound selected from the group consisting of xanthan gum, guar gum, hydroxypropylmethyl cellulose, hydroxypropyi cellulose, methylceilulose, hydroxyethylcellulose, polyvinyl pyrrolidone, alginates, acacia, tragacanth, carboxylmethylcellulose and sodium carboxylmethyice!lu!ose (Na CMC). Suspending agents may be employed in an amount within the range from about 0 to about 20% by weight of the powder formulation, and from about 0 to about 10% by weight of the oral suspension.
Sweeteners for use in the formulations of the invention may be any convenient agents known in the art for this purpose and may be selected from any compatible sweetener groups such as natural sweeteners like sucrose, fructose, dextrose, maltose, mannose, galactose, xylitol, sorbitol, or mannitol, glycerin as well as artificial sweeteners such as sodium cyclamate, sodium saccharin aspartame, acesulfam K and sucraiose. The composition comprises at least one sweetener. Preferably, sucraiose is used as sweetener.
Flavors and flavor modifiers or taste modifiers can also be used to further improve the taste and can be any convenient agents known in the art for this purpose and include, but are not limited to, orange flavor, vanilla flavor, licorice flavor, orange vanilla flavor, creme de mint, cherry flavor, cherry vanilla flavor, berry mix flavor, mandarin orange flavor and tutti-frutti- flavor, and combinations thereof. The composition comprises at least one flavoring or taste modifier. Preferably, orange flavor is used.
Preservatives can be any convenient agents known in the art for this purpose such as methy!paraben and propylparaben, benzoic acid, sodium benzoate, potassium sorbate. The composition comprises at least one preservative. Preferably, preservative agent used is mixture of methylparaben sodium and propylparaben sodium.
Also wetting agents can be used in the composition such as polyethylene glycol stearates, (polyethylene glycol 400 monostearate), Poloxamer, Polysorbates.
Glidants can also optionally be used such as silicon dioxide, talc and titanium dioxide..
Methylparaben sodium, propylparaben sodium, potassium citrate, sucralose and Xanthan gum are dissolved in deionized water for preparing a palatable suspension with drug concentration of 20mEq/5 ml of potassium citrate. Glycerol and orange oil are added. Then the volume is completed with water and it is filled into glass or plastic (HDPE) 250 ml bottles for desired fill weight.
Example 1:
Claims
1. A pharmaceutical oral suspension comprising potassium citrate wherein the amount of potassium citrate monohydrate in 5ml is between 540mg (5mEq) and 2160mg (20mEq).
2. A pharmaceutical oral suspension according to claim 1 wherein the amount of potassium citrate monohydrate in 5ml is 2160mg (20mEq).
3. A pharmaceutical suspension according to claim 1-2 wherein it comprises at least one compound selected from the group consisting of xanthan gum, guar gum, hydroxypropylmethyi cellulose, hydroxypropyi cellulose, methylcellulose, hydroxyethylcellulose, polyvinyl pyrroiidone, alginates, Acacia, Tragacanth, carboxylmethy!cel!u!ose and sodium carboxylmethylcellulose (Na CMC) as suspending agents.
4. A pharmaceutical suspension according to claim 3 wherein suspending agent is xanthan gum.
5. A pharmaceutical suspension according to claim 4 wherein the amount of xanthan gum is from 0.05 to 2 grams in 100 ml of suspension.
6. A pharmaceutical suspension according to claims 1-5 wherein it comprises at least one co-solvent.
7. A pharmaceutical suspension according to claim 6 wherein co-solvent is glycerol.
8. A pharmaceutical suspension according to claims 1-7 wherein it comprises at least one sweetening agent.
9. A pharmaceutical suspension according to claim 8 wherein sweeting agent is sucralose.
10. A pharmaceutical suspension according to claims 1-9 wherein it comprises at least one preservative agent.
11. A pharmaceutical suspension according to claim 10 wherein preservative agent is mixture of methylparaben sodium and propylparaben sodium.
12. A pharmaceutical suspension according to previous claims wherein it uses for the treatment and preventing the formation of the kidney stones.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2015/000136 WO2016159897A1 (en) | 2015-04-01 | 2015-04-01 | Potassium citrate suspension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2015/000136 WO2016159897A1 (en) | 2015-04-01 | 2015-04-01 | Potassium citrate suspension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2016159897A1 true WO2016159897A1 (en) | 2016-10-06 |
Family
ID=53039559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2015/000136 WO2016159897A1 (en) | 2015-04-01 | 2015-04-01 | Potassium citrate suspension |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2016159897A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11395931B2 (en) | 2017-12-02 | 2022-07-26 | Mighty Fire Breaker Llc | Method of and system network for managing the application of fire and smoke inhibiting compositions on ground surfaces before the incidence of wild-fires, and also thereafter, upon smoldering ambers and ashes to reduce smoke and suppress fire re-ignition |
| US11400324B2 (en) | 2017-12-02 | 2022-08-02 | Mighty Fire Breaker Llc | Method of protecting life, property, homes and businesses from wild fire by proactively applying environmentally-clean anti-fire (AF) chemical liquid spray in advance of wild fire arrival and managed using a wireless network with GPS-tracking |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888182A (en) | 1983-04-11 | 1989-12-19 | Board Of Regents Of The University Of Texas System | Compositions and methods of treating calcium renal stones |
| US4904478A (en) | 1983-08-11 | 1990-02-27 | Mission Pharmacal Company | Slow-release sodium fluoride tablet and method for treatment of osteoporosis |
| US4966776A (en) | 1983-04-11 | 1990-10-30 | Board Of Regents, The University Of Texas System | Compositions and methods of treating calcium renal stones |
| US5759579A (en) * | 1996-12-05 | 1998-06-02 | American Home Products Corporation | Pharmaceutical suspension systems |
| WO2007011740A2 (en) * | 2005-07-15 | 2007-01-25 | Mission Pharmacal Co. | A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis |
| US20080131504A1 (en) | 2006-12-01 | 2008-06-05 | Mission Pharmacal Co. | Short Term Slow Release Drug Delivery System |
| WO2014051443A1 (en) | 2012-09-27 | 2014-04-03 | Mendoza Wendell G | Method for producing extended-release potassium citrate wax matrix tablet |
| US20140271929A1 (en) * | 2013-03-15 | 2014-09-18 | New York University | Citrate containing beverage |
-
2015
- 2015-04-01 WO PCT/TR2015/000136 patent/WO2016159897A1/en active Application Filing
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888182A (en) | 1983-04-11 | 1989-12-19 | Board Of Regents Of The University Of Texas System | Compositions and methods of treating calcium renal stones |
| US4966776A (en) | 1983-04-11 | 1990-10-30 | Board Of Regents, The University Of Texas System | Compositions and methods of treating calcium renal stones |
| US4904478A (en) | 1983-08-11 | 1990-02-27 | Mission Pharmacal Company | Slow-release sodium fluoride tablet and method for treatment of osteoporosis |
| US5759579A (en) * | 1996-12-05 | 1998-06-02 | American Home Products Corporation | Pharmaceutical suspension systems |
| WO2007011740A2 (en) * | 2005-07-15 | 2007-01-25 | Mission Pharmacal Co. | A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis |
| US20080131504A1 (en) | 2006-12-01 | 2008-06-05 | Mission Pharmacal Co. | Short Term Slow Release Drug Delivery System |
| WO2014051443A1 (en) | 2012-09-27 | 2014-04-03 | Mendoza Wendell G | Method for producing extended-release potassium citrate wax matrix tablet |
| US20140271929A1 (en) * | 2013-03-15 | 2014-09-18 | New York University | Citrate containing beverage |
Non-Patent Citations (2)
| Title |
|---|
| ANONYMOUS: "tricitrates", July 2012 (2012-07-01), XP002740483, Retrieved from the Internet <URL:http://www.drugs.com/pro/tricitrates.html> * |
| CHARLES Y C PAK ET AL: "Augmentation of RenalCitrateExcretionby OralPotassium CitrateAdministration: TimeCourse, DoseFrequency Schedule, and Dose-Response Relatiooship", THE JOURNAL OF CLINICAL PHARMACOLOGY, vol. 24, 7 March 2013 (2013-03-07), pages 19 - 26, XP055193525, ISSN: 0091-2700 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11395931B2 (en) | 2017-12-02 | 2022-07-26 | Mighty Fire Breaker Llc | Method of and system network for managing the application of fire and smoke inhibiting compositions on ground surfaces before the incidence of wild-fires, and also thereafter, upon smoldering ambers and ashes to reduce smoke and suppress fire re-ignition |
| US11400324B2 (en) | 2017-12-02 | 2022-08-02 | Mighty Fire Breaker Llc | Method of protecting life, property, homes and businesses from wild fire by proactively applying environmentally-clean anti-fire (AF) chemical liquid spray in advance of wild fire arrival and managed using a wireless network with GPS-tracking |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102218334B1 (en) | Enhanced stability of novel liquid compositions | |
| ES2259098T3 (en) | COMPOSITIONS THAT INCLUDE IPATROPY AND XYLOMETAZOLINE FOR THE TREATMENT OF THE COMMON COLD. | |
| JP2004535370A (en) | Liquid pharmaceutical composition with masked taste | |
| EP1603550B1 (en) | Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetic acid | |
| US11529333B2 (en) | Oral pharmaceutical composition comprising zonisamide and process of preparation thereof | |
| EP3003384B1 (en) | Oral solution comprising atomoxetine hydrochloride | |
| US20130109729A1 (en) | Pharmaceutical composition | |
| JP2590156B2 (en) | Pharmaceutical composition for oral administration | |
| WO2016159897A1 (en) | Potassium citrate suspension | |
| US20060269598A1 (en) | Antihistaminic/Decongestant/Anticholinergic Compositions and Methods of Use | |
| EP2662077B1 (en) | Effervescent compositions containing n-acetylcysteine | |
| US20060100271A1 (en) | Stabilized aqueous ranitidine compositions | |
| US20060269597A1 (en) | Tannate Compositions and Methods of Use for the Treatment of Respiratory Tract Conditions | |
| KR20200121835A (en) | Multi-use Torasemide Composition | |
| US20070248667A1 (en) | Tannate Compositions and Methods of Use | |
| EP1374874B1 (en) | Liquid antacid compositions | |
| EP3678498B1 (en) | Composition for calcium supplementation | |
| WO2014191414A1 (en) | Syrup formulation of salbutamol | |
| PT835653E (en) | LIQUID ANTI-LIQUID COMPOSITIONS | |
| WO1999004788A1 (en) | Aqueous compositions comprising ranitidine and lcmt sucrose | |
| WO2008039792A1 (en) | Stable pharmaceutical compositions of preserved formulation of ranitidine, process for making the same, and methods of their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15719871 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15719871 Country of ref document: EP Kind code of ref document: A1 |